| Primary Identifier | MGI:5575757 | Allele Type | Transgenic |
| Attribute String | Inducible, Recombinase | Gene | Tg(Tnfrsf19-cre/ERT2)1Kori |
| Strain of Origin | C57BL/6NCrl | Induced With | tamoxifen |
| Is Recombinase | true | Is Wild Type | false |
| molecularNote | The transgene was derived from the mouse bacterial artificial chromosome (BAC) RP23-166C22, which contains the entire tumor necrosis factor receptor superfamily 19 (Tnfrsf19; also called Troy) gene with 65 kb of 5' and 88 kb of 3' flanking genomic DNA. A cDNA encoding a fusion protein comprising cre recombinase joined to a modified human estrogen receptor (creERT2), followed by the rabbit beta-globin polyadenylation signal, was inserted in-frame at the translation initiation codon in the second exon; the timing and location of creERT2 expression are determined by Tnfrsf19 regulatory sequences, but it remains inactive until bound to tamoxifen and transported to the nucleus. X-Gal staining and in-situ hybridization with a Tnfrsf19 anti-sense RNA of E14 embryos bearing this transgene and the Gt(ROSA)26Sortm1Sor cre reporter collected one day after their dams' treatment with tamoxifen showed coordinate cre recombinase-induced lacZ and endogenous Tnfrsf19 mRNA expression, notably in the telencephalon, cerebral plate, ear, maxilla, vibrissae, dorsal root ganglia, and mammary gland primordia. Three transgenic founder lines were obtained, all exhibiting virtually identical Cre recombinase activity patterns. |
